Article Text

PDF
Magnitude of Peroxisome Proliferator-Activated Receptor-γ Activation is Associated With Important and Seemingly Opposite Biological Responses in Breast Cancer Cells
  1. Carl E. Clay,
  2. Andrew M. Namen,
  3. Gen-ichi Atsumi,
  4. Anthony J. Trimboli,
  5. Alfred N. Fonteh,
  6. Kevin P. High,
  7. Floyd H. Chilton
  1. 1From the Department of Internal Medicine (C.E.C, A.M.N., G.A., A.J.T., A.N.F., K.P.H., F.H.C.), Wake Forest University School of Medicine, Winston-Salem, NC
  2. 2Section of Pulmonary and Critical Care Medicine (C.E.C, A.M.N., A.J.T., A.N.F., F.H.C.), Wake Forest University School of Medicine, Winston-Salem, NC
  3. 3Section of Infectious Diseases (G.A.,K.P.H.), Wake Forest University School of Medicine, Winston-Salem, NC
  4. 4Department of Physiology/Pharmacology (F.H.C.), Wake Forest University School of Medicine, Winston-Salem, NC.
  1. Address correspondence to: Kevin P. High, MD, MSc, Department of Internal Medicine, Section of Infectious Diseases, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1042. Email khigh{at}wfubmc.edu
  2. This work was supported by NIH Grants RO1AI42022, AI24985, and AI42022, AICR grant 97B108, and Cancer Center Grant 2-P30-CA12197-25 (to Wake Forest University School of Medicine). C.E.C. received support through a grant from the United States Army Medical Research Acquisition Activity (USAMRAA) DAMD17-00-1-0489, Fort Detrick, Md.
  3. *These authors contributed equally to this work.

Abstract

Background The nuclear receptor peroxisome proliferator-activated receptor-γ (PPARγ) has become a potential target for the prevention and treatment of breast cancer. However, recent in vitro and in vivo studies have raised the question of whether activation of PPARγ leads to the promotion or reduction of tumor formation. Studies using several cancer cell lines, animal models, and a variety of PPARγ agonists have shown discordant results, including changes in cellular proliferation, differentiation, and apoptosis of cancer cells and tumors.

Methods We studied the effects of low-, moderate-, and high-dose treatment of the PPARγ ligands 15-deoxy-Δ12,14 prostaglandin J2 (15dPGJ2) and troglitazone (TGZ) on parameters of cell growth, differentiation, and apoptosis in the epithelial breast cancer cell line MDA-MB-231.

Results The biologic effects of these compounds depend largely on ligand concentration and the degree of PPARγ activation. For example, low concentrations of 15dPGJ2 (<2.5 μM) and TGZ (<5 μM) increased cellular proliferation, but concentrations of 15dPGJ2 >10 μM and of TGZ at 100 μM blocked cell growth. TGZ (100 μM) slowed cell cycle progression, and 15dPGJ2 (10 μM) caused an S-phase arrest in the cell cycle and induced morphological characteristics consistent with apoptosis. Expression of CD36, a marker of differentiation in these cells, was induced by 2.5 μM 15dPGJ2 or 5 to 100 μM TGZ. However, higher concentrations of 15dPGJ2 did not alter CD36 expression. Transcriptional activation studies demonstrated that 15dPGJ2 is a more potent PPARγ ligand than TGZ. Regardless of the ligand used, though, low transcriptional activation correlated with an increased cellular proliferation, whereas higher levels of activation correlated with cell cycle arrest and apoptosis.

Conclusions PPARγ activation induces several important and seemingly opposite changes in neoplastic cells, depending on the magnitude of PPARγ activation. These data may explain, at least in part, some of the discordant results previously reported.

Keywords
  • PPARγ
  • breast cancer
  • cell cycle arrest
  • differentiation
  • apoptosis

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.